8-KLeadership Changes

BOSTON SCIENTIFIC CORP 8-K Report, Executive Changes (Oct 5, 2020)

Filed October 5, 2020For Securities:BSX

Summary

Boston Scientific Corporation (BSX) announced a significant update regarding its Board of Directors' compensation. Effective for the remainder of the 2020 term, the annual cash retainer for non-employee directors will be restored to two-thirds of the originally approved amount. This restoration follows an earlier temporary reduction to one-half of the approved amount, implemented in April 2020 due to COVID-19 related uncertainties. The decision to restore compensation is driven by the company's stronger-than-expected business performance. This positive business trend indicates a potential rebound and improved financial outlook for Boston Scientific, which is a key signal for investors assessing the company's operational resilience and future prospects. The change will be reflected in payments made during the fourth quarter of 2020.

Key Highlights

  • 1Board of Directors' cash retainer restored to two-thirds of the original amount.
  • 2Restoration is effective for the remainder of the 2020 term.
  • 3The previous reduction to one-half of the retainer was a temporary measure due to COVID-19 uncertainty.
  • 4The restoration is attributed to stronger business results than initially anticipated.
  • 5A payment related to the restored retainer is expected in the fourth quarter of 2020.
  • 6Directors opting for equity in lieu of cash will receive an additional grant valued at one-sixth of the annual cash retainer.

Frequently Asked Questions

The board's annual cash retainer was temporarily reduced to one-half of the approved amount starting at the 2020 Annual Meeting of Stockholders due to the disruption and uncertainty caused by the evolving COVID-19 pandemic and its anticipated impact on company operations.

The annual cash retainer for non-employee directors will be restored to two-thirds of the previously approved amount for the remainder of the 2020 term. This is an increase from the one-half amount previously in effect.

The restoration is a direct result of Boston Scientific's business performance proving stronger than the company's prior expectations, indicating a positive operational trend.

A payment reflecting the restored annual cash retainer is expected to be made during the fourth quarter of 2020.